Back to Search
Start Over
Biosimilars of adalimumab: the upcoming challenge in IBD
- Source :
- Expert opinion on biological therapy. 19(10)
- Publication Year :
- 2019
-
Abstract
- Introduction: Biosimilars represent great potential in cost saving and re-investment opportunities in healthcare and allow patients greater access to effective mAbs. Infliximab biosimilars are succ...
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Clinical Biochemistry
Inflammatory bowel disease
03 medical and health sciences
0302 clinical medicine
Drug Discovery
Adalimumab
Medicine
Humans
Intensive care medicine
Biosimilar Pharmaceuticals
health care economics and organizations
Pharmacology
Crohn's disease
Clinical Trials as Topic
business.industry
Antibodies, Monoclonal
Biosimilar
medicine.disease
Inflammatory Bowel Diseases
Ulcerative colitis
Infliximab
Cost savings
030104 developmental biology
030220 oncology & carcinogenesis
business
medicine.drug
Half-Life
Subjects
Details
- ISSN :
- 17447682
- Volume :
- 19
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Expert opinion on biological therapy
- Accession number :
- edsair.doi.dedup.....265da9d108ad42084612508f3cd2922f